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Abstract
Most human antibodies against HPV16 can be blocked by the monoclonal antibody H16.V5. To investigate whether H16.V5 and human
sera recognize similar epitopes, hybrid capsids containing different parts of HPV16 and HPV11 were evaluated for reactivity with human
sera. The antibody responses among HPV 16-/HPV11sera to HPV11 and to hybrid capsids containing the HPV11 C-terminus were
strongly correlated. The antibody responses among HPV 16/HPV11-sera to HPV16 and to a hybrid containing the HPV16 C-terminus
were correlated and there was also reactivity with a hybrid containing the H16.V5 epitope in the HPV11 backbone. Several HPV16-/11-
children’s sera were reactive with hybrid capsids, implying that a native capsid structure is essential for serological specificity. For both
HPV16 and HPV11, the major serologic reactivity was directed toward the C-terminal part of the protein and the H16.V5 binding site
appeared to be a major serologically reactive epitope of HPV16.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human papillomavirus type 16 (HPV16) is the most
prevalent genital HPV type and is an established cause of
cervical intraepithelial neoplasia (CIN) (Schiffman et al.,
1993) and anogenital cancers (IARC 1995). Recent results
with animal models of papillomavirus-associated disease
have demonstrated the protective effects generated by pap-
illomavirus viruslike particles (VLPs) composed of the vi-
rus major coat protein, L1 (Breitburd et al., 1995; Chris-
tensen et al., 1996b; Jansen et al., 1995; Kimbauer et al.,
1996; Stanley et al., 2001; Suzich et al., 1995).
HPV-neutralizing assays are essential for testing the ac-
tivity of mouse monoclonal antibodies, polyclonal anti-VLP
antisera, and sera from patients with HPV infections and/or
vaccines. Studies using papillomavirus neutralizing mono-
clonal antibodies (N-MAbs) have demonstrated that viral
type-specific surface conformational epitopes on intact viri-
ons or VLPs are the predominant neutralizing epitopes
(Christensen et al., 1990; Ludmerer et al., 1996; Roden et
al., 1997). Both the epitopes recognized by type-specific
neutralizing MAbs (Christensen et al., 1996a) and the
epitopes recognized by the type-restricted human antibodies
(Dillner et al., 1995) are dependent on the conformation of
the capsid. Strictly type-specific serological responses have
generally been found if intact, correctly folded VLP are
used. The exception is between HPV6 and -11, which have
been shown to contain both shared epitopes and type-spe-
cific epitopes on intact capsids. However, disrupted or not
correctly folded VLPs expose epitopes with limited HPV
type-specificity (Christensen et al., 1994, 1996c).
Current HPV vaccine strategies are focused on using a
mixture of one or more VLPs constructed from wild-type
L1 genes of clones of certain HPV types such as HPV11 and
-16 (Evans et al., 2001; Harro et al., 2001; Pastrana et al.,
2001; Schiller and Hidesheim, 2000; Zhang et al., 2000).
Hybrid L1 proteins from different HPV types can be con-
structed that retain VLP-assembly properties. Such hybrid
VLPs retain type-specific conformational neutralizing
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epitopes, can map noncontiguous regions of L1 that consti-
tute type-specific conformational neutralizing epitopes rec-
ognized by N-MAbs and can trigger polyclonal antibodies
that can neutralize antigenically unrelated HPV type (Chris-
tensen et al., 2001). The type-specific and neutralizing
mouse monoclonal antibody H16.V5 uniformly recognizes
also distantly related HPV16 strains (Cheng et al., 1995).
The antibodies in human sera that are reactive with intact
HPV type 16 capsids are also type-specific and reactive with
HPV16 capsids also from distantly related strains (Cheng et
al., 1995). Most antibodies in human sera can be completely
blocked by the H16.V5 MAb, whereas blocking is not seen
with other MAbs of similar affinity that also recognize
conformational surface epitopes of HPV16 (Wang et al.,
1997a). This suggested that most antibodies in human sera
that are reactive with intact HPV16 capsids recognize the
same or closely related major antigenic determinants as
does the H16.V5 MAb. As other explanations were also
possible, we wished to further investigate whether the
H16.V5 epitope is a major epitope recognized by human
sera. Therefore, the serological reactivity of hybrid capsids
composed of different parts of HPV16 and HPV11 L1, with
and without the V5 epitope, was investigated in this study.
Results
Reactivity of hybrid VLPs with type-specific MAbs
To verify whether the hybrid VLPs contained the type-
specific conformation-dependent neutralizing epitopes that
would be expected, monoclonal antibodies H16.V5
(HPV16 neutralizing), H11.F1 (HPV11 neutralizing), and
H11.H3 (HPV11 neutralizing) were reacted with HPV16
L1, HPV11 L1, and the three hybrid VLPs (H11:16[172-
505], H11:16[FGHI], and H16:11[171-505]) by
ELISA. As expected, the reactivities of MAbH16.V5 to
HPV16 and MAbs H11.F1 and H11.H3 to HPV11 were
type-specific. Hybrid H11:16[172-505] had very high re-
activity to H16.V5 and some reactivity to HPV11F1, but
no reactivity to HPV11 H3. Hybrid H11:16[FGHI]
showed high reactivity both to HPV16 V5 and HPV11
F1, but no reactivity to HPV11 H3. Hybrid H16:11[171–
505] showed only high reactivity to HPV11H3 but no
reactivity to H16.V5 and HPV11F1 (Table 1).
Reactivity of HPV16/11 hybrid VLPs with human serum
samples
The antibody responses among HPV16/HPV11 sera
to HPV11 and to the hybrids that contained the HPV11
C-terminus (H11:16[FGHI] and H16:11[171–505]) were
strongly correlated (Fig. 2D) but with generally higher an-
tibody levels against H11:16[FGHI] and H16:11[171–
505] (Fig. 2B and C; Table 2).
The antibody responses among HPV16/HPV11
sera to HPV16 and to the hybrid containing the HPV16
C-terminus (H11:16[172–505]) were also correlated (Fig.
3A). Eight-four percent of these sera also reacted with
H11:16[FGHI] and all 19 serum samples that were
Table 1
Reactivity of hybrid VLPs with type-specific monoclonal antibodies
Monoclonal antibody Viruslike particle (VLP) antigen (ELISA absorbance)
HPV16 HPV11 H11:16[172–505] H11:16[FGHI] H16:11[171–505]
H16.V5 2.429 0.010 2.097 2.106 0.014
H11.F1 0.047 2.452 0.253 1.667 0.023
H11.H3 0.040 1.300 0.043 0.025 1.298
Note. Monoclonal antibodies H16.V5 (HPV16 neutralizing) and H11.F1, H11.H3 (HPV11 neutralizing) were reacted with HPV16 VLPs, HPV11 VLPs,
and the three hybrid VLPs (H11:16[172–505], H11:16[FGHI], and H16:11[171–505]) by ELISA.
Fig. 1. Schematic depiction of the HPV16/11 hybrid VLPs H11:16[172-505], H16:11[171-505] and H11:16[FGHI]: hybrid VLP H11:16[172-505] contains
the aminoterminal part of HPV11 and the carboxyterminal part of HPV16; hybrid VLP H16:11[171-505] contains the aminoterminal part of HPV16 and the
carboxyterminal part of HPV11; hybrid VLP H11:16[FGHI] contains two non-contiguous hypervariable regions of HPV16 L1 containing the FG and HI
loops transplanted into HPV11 L1 backbone.
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strongly HPV16-positive (dOD  0.4), but HPV11-neg-
ative, had acquired reactivity with the hybrid H11:
16[FGHI] that was composed of HPV11 with only the
two small loops forming the H16.V5 epitope in HPV16
being added (Fig. 3B).
Many HPV16-/11- control sera from children had de-
tectable reactivities to H11:16[FGHI] and to H16:
11[171–505] with dOD levels increasing up to three-fold
(Table 2) and up to 40% of control sera becoming “pos-
itive” (dOD 0.1) (Fig. 4A and B). These reactivities
were highly correlated to the reactivities (below cutoff)
to HPV11 (Fig. 4A and B). The reactivities of the
HPV11-/16- control sera with the H11:16[FGHI] and
H16:11[171–505] hybrid VLPs were also strongly corre-
lated to each other (Fig. 4C).
Serological reactivities with the hybrid containing the
homologous N-terminal part (HPV16-/11 samples with
hybrid H11:16[172-505] and HPV16/11- samples with
H16:11[171–505]) were common but rather weak and not
directly correlated to the titres against homologous virus.
However, a few strongly reactive sera were found (Figs. 2A
and 3C).
Fig. 2. Reactivity of HPV16/11 hybrid virus-like particles with HPV16 negative, but HPV11 positive human serum samples. (A) Hybrid H11:16[172-505]
vs HPV11. (B) Hybrid H11:16[FGHI] vs HPV11. (C) Hybrid H16:11[171-505] vs HPV11. (D) Hybrid H11:16[FGHI] vs hybrid H16:11[171-505].
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Hybrid VLPs and exposure of epitopes normally displayed
only on disrupted VLPs
A panel of MAbs that in a previous study (Christensen et
al., 1996c) were found to react preferentially with denatured
HPV16 and 11VLPs were tested for reactivity to intact
HPV16/11 hybrid VLPs, with intact and denatured HPV16,
and 11 VLPs as negative and positive controls. Monoclonal
antibody H16.B20 that reacts with both denatured HPV11
and 16 and the MAbs H16.V5, H11.H3 and H11.F1 were
used as positive control MAbs. The epitope defined by the
monoclonal antibody H16.D9 was exposed on the intact
hybrid VLPs, but only exposed on disrupted HPV11 and 16
VLPs (Table 3). Several other MAbs were also tested but
revealed no evidence of additional epitope exposure on
hybrid VLPs (data not shown).
Discussion
It has been previously shown that most antibodies in
human sera that are reactive with intact HPV type 16 cap-
sids could be blocked by the single monoclonal antibody
H16.V5 (Wang et al., 1997a) and that VLPs prepared from
H11.16 hybrid L1 proteins retained conformationally de-
pendent neutralizing epitopes that could be recognized by
H16.V5 (Christensen et al., 2001). In the present study, we
demonstrated that all 19 human sera that contained high
levels of antibodies to HPV16, but were negative to HPV11,
became reactive with VLPs consisting of HPV11 plus the
H16.V5 epitope from HPV16. These data support earlier
observations suggesting that the V5-defined epitope is a
major epitope recognized by human sera after infection with
HPV16. Overall, our data on the reactivity of human sera
was in good agreement with the results of studies charac-
terizing the neutralizing epitopes of HPV11 and HPV16
using monoclonal antibodies. Hybrid H11:16[172–505] re-
tained neutralizing epitopes for some HPV11 MAbs (H11.
B2, G5, and F1) and for most HPV16 MAbs (H16.V5, E70,
U14, 2F, 3A, 4A, 5A, and 6F). The reciprocal hybrid L1
construct H16:11[171–505] retained neutralizing epitopes
for other MAbs: HPV11 MAb H11.H3 and HPV16 MAbs
H16.7E and 9A. Wild-type levels of binding for the H16.V5
MAb as well as several other HPV16 MAbs (1A, 2F, 5A,
6F) were obtained with H11:16[FGHI], which contained
two hypervariable regions of HPV16 (aa 266–297 and 339–
365 or the FG and HI loops) in the HPV11 L1 backbone
(Christensen et al., 2001).
We found that most HPV16-reactive human sera had
similar binding properties as the H16.V5 group of MAbs
(V5, 1A, 2F, 5A, 6F). The existence of a serological re-
sponse to the N-terminal part of HPV16 L1 was suggested
by the strong reactivity of a few HPV16/11- sera with
H16:11[171–505]. This minor reactivity resembled the re-
activity pattern of a few HPV16 neutralizing MAbs (7E and
9A).
For HPV11, the reactivity of several neutralizing MAbs
(B2, G5, F1) with the N-terminal part of HPV11 L1 did not
correspond well with the reactivity of human sera, as only
two HPV11/16- serum samples were found that reacted
with hybrid H11:16[172–505]. The major serological reac-
tivity against HPV11 resembled the reactivity of MAb
H11.H3 that reacted with the C-terminal part of HPV11.
Addition of the H16.V5 epitope in the H16:11[171–505]
hybrid similarly did not affect the binding of HPV11-posi-
tive human sera, nor did it affect the binding of the HPV11
MAbs. Rabbit polyclonal anti-HPV-11 L1 VLP responses
also appear to react predominantly with the C-terminal
region of HPV-11 L1 (Giroglou et al., 2001). The fact that
the reactivities of HPV11/16- human sera with HPV11,
H11:16[FGHI], and H16:11[171–505] were strongly cor-
related indicated that the same epitope(s) were displayed on
these VLPs. However, there was a remarkable difference in
the level of antibody reactivity for these three hybrid VLPs,
with H11:16[FGHI] giving almost 3 times higher reactiv-
ity on average. This difference was seen despite using sim-
ilar amounts of VLPs that were titrated to be optimal con-
centrations of VLP antigen in each ELISA assay. A possible
explanation is that there may be subtle differences in the
surface exposure of conformationally constrained epitopes
on hybrid VLPs.
A large proportion of HPV11-/16- control serum samples
from children became serologically reactive. This reactivity
was strongly correlated to the weak, but below cutoff reac-
tivities (0.099–0.001) seen with wild-type HPV11 VLPs.
As this low reactivity was common among children, it could
not have been induced by sexually transmitted HPV infec-
tions. It is possible that these weak but positive responses
Table 2
Reactivity of HPV16/11 hybrid VLPs with human serum samples
Type of human serum samples Viruslike particle (VLP) antigen
HPV16 HPV11 H11:16[172–505] H11:16[FGHI] H16:11[171–505]
HPV16/HPV11 0.031 0.563 0.083 1.480 0.677
HPV16/HPV11 0.518 0.058 0.208 0.301 0.141
HPV16/HPV11 0.028 0.046 0.060 0.145 0.068
Note. The HPV16, HPV11, and the HPV16/11 hybrid VLPs were tested in ELISA for reactivity with 32 HPV16 but HPV11 serum samples, 64
HPV16 but HPV11 serum samples and 23 HPV16, HPV11 control serum samples from children. The table shows the ELISA mean absorbance values
for each serum sample group.
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may represent cross-reactivity with some other viruses or
that they may have been induced by nonsexually transmitted
HPV infections. The HPV L1 protein is highly conserved
among the papillomaviruses and is well known to contain
broadly cross-reactive internal epitopes (Jenson et al.,
1980). The epitope defined by the H16.D9 MAb is prefer-
entially exposed on disrupted VLPs and the increased ex-
posure of this epitope on two hybrid VLPs appeared to
correlate with an increased reactivity with control serum
samples (confer Fig. 4A and B with Table 3). Both for HPV
serology and for HPV vaccinology, there is a definite need
to define quality control methods that will detect if prepared
VLPs have an intact conformation with appropriate expo-
sure of type-specific neutralizing epitopes and minimal ex-
posure of broadly cross-reactive, nonneutralizing epitopes.
Our results with the H16.D9 MAb suggest that the hybrid
VLPs were not adequately folded and exposed a cross-
reactive internal epitope. The data further suggest that ab-
sence of reactivity with the H16.D9 is a desirable property
of VLP preparations intended for type-specific serology or
vaccination. Our finding that certain hybrid VLPs had re-
activity with control serum samples underline the need for
the use of sizable and well-characterized negative control
serum panels for epitope mapping studies using polyclonal
sera and also emphasize the need for immunological quality
control testing of VLP preparations.
The increased background cross-reactivity seen with
H11:16[FGHI] complicates the interpretation of the data.
Fig. 3. Reactivity of HPV16/11 hybrid virus-like particles with HPV16 positive, but HPV11 negative human serum samples. (A) Hybrid H11:16[172-505]
vs HPV11. (B) Hybrid H11:16[FGHI] vs HPV11. (C) Hybrid H16:11[171-505] vs HPV11. (D) Hybrid H11:16[FGHI] vs hybrid H16:11[171-505].
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Whereas all high HPV16 sera acquired reactivity with
HPV11 after transplanting the H16.V5 binding site, more
than half of low HPV16 sera also acquired this reactivity.
The induced reactivities of these weakly HPV16 sera
against H11:16[FGHI] resembled the reactivity of the
control sera in that they were, for example, strongly corre-
lated to their below-cutoff reactivities to HPV11 [r 
0.7469, data not shown (see Fig. 4A)]. The moderately
strong correlation of the antibody levels against HPV16 and
against H11:16[FGHI] (Fig. 3B) is likely to be at least in
part attributable to the background cross-reactivity. It is also
possible that the H11:16[FGHI] hybrid does not appro-
priately display the epitope recognized by human sera or
that there may be additional important epitopes in the
HPV16 C-terminus.
In conclusion, for both HPV11 and HPV16, the major
serologic reactivity was found to be directed against the
C-terminus of L1 as evidenced by the high correlation of the
antibody levels. Transplanting the small V5 binding site
from HPV16 to HPV11 resulted in VLPs that will react with
all strongly HPV16 but HPV11 human serum samples.
As only a minority of control samples acquired this reac-
tivity, and at much lower levels ( half the mean dOD), the
H16.V5 binding site does appears to be an important epitope
recognized by human sera. The fact that some hybrid VLPs
had increased reactivity with control serum samples and
also exposed the H16.D9-defined internal, cross-reactive
epitope implies that maintaining the native capsid structure
is essential for serological specificity.
Materials and methods
In order to investigate if human sera containing IgG
reactivity to HPV16 L1 VLPs or HPV11 L1 VLPs are also
able to recognize hybrid VLPs, serum samples that were
HPV16 but HPV11- or HPV16- but HPV11 were se-
lected from three previous serological studies. Study 1 in-
vestigated attack rates and seroprevalences of human pap-
illomavirus types 11, 16, and 33 among a high-risk
population for cervical cancer, the Shanxi province, China.
In total 1196 high school students/teachers (570 men and
626 women, mean age 16 years, range 14–35 years) and
170 couples (mean age 24 years, range 20–35 years) at-
tending the mandatory serological health control before
marriage donated serum samples at enrollment and 12
months later. Study 2 investigated the human papillomavi-
rus antibody response among 216 women (mean age 53
years, range 23–88 years) with untreated primary invasive
cervical cancer admitted to the Karolinska Hospital, Stock-
holm, Sweden. Study 2 also contained 243 age and sex-
matched healthy control women (Wang et al., 1997b). Study
3 investigated sexual behavior and the risk of HPV infection
in 188 serum samples from 94 teenage girls (mean age 16.1
years) donated at enrollment and at a follow-up 2 years
later. Forty-five samples were from virgins, whereas the
other samples were from sexually experienced girls. None
of the virgin girls had HPV DNA in the cervix (by PCR) or
serum antibodies against HPV16 or 33 (Andersson-Ellstrom
et al., 1996). HPV16HPV11- and HPV16-HPV11 sam-
ples from these studies were retested with HPV16 and
HPV11 in parallel with the hybrid VLPs. In addition to
these, children serum samples were selected from a study
that surveyed the seroprevalence of human papillomavirus
types 16, 18, and 33 among 1031 children up to 13 years of
age, whose serum samples had been submitted for serolog-
ical analyses of non-HPV-related diseases and were ob-
tained from the Department of Clinical Virology of the
Karolinska Hospital and the Department of Paediatrics of
the Huddinge Hospital, both in Stockholm, Sweden (af
Geijersstam et al., 1999). Serum samples from children in
the age group 2–10 years that had been found to be HPV16-
were now also tested with HPV11 and retested with HPV16
in parallel with the hybrid VLPs to ensure that they were
both HPV16- and HPV11-. In total, 32 HPV16/HPV11-
serum samples, 64 HPV16-/HPV11 serum samples, and
23 HPV16-/HPV11- serum samples were found.
Construction of HPV16/11 hybrid VLPs
Hybrid H11:16[FGHI] was constructed by replacing
two noncontiguous hypervariable regions of HPV16 L1
containing the FG and HI loops (Chen et al., 2000) into the
HPV11 L1 backbone by first engineering unique restriction
enzyme sites into the HPV11 L1 sequence at the boundaries
of the hypervariable regions of choice. The hypervariable
regions within the HPV11 L1 gene were removed by re-
striction digestion and then replaced by the complementary
HPV16 hypervariable region (obtained by PCR amplifica-
tion of HPV16 L1). This VLP is reactive with the HPV16-
specific MAb H16.V5. Hybrid H11:16[172–505] contains
the aminoterminal part of HPV11 and the carboxyterminal
part of HPV16, whereas hybrid H16:11[171–505] contains
the aminoterminal part of HPV16 and the carboxyterminal
part of HPV11 (Fig. 1). They were prepared by standard
molecular biological techniques. HPV11 L1 was obtained
from the HPV11 genome established in the athymic mouse
xenograft system, and HPV16 L1 was obtained by PCR
amplification from DNA extracted from CaSki cells. Hybrid
L1 molecules were designed to ensure that the two L1
fragments were joined in-frame to generate a continuous L1
reading frame that retained conserved features of all HPV
L1 molecules. The H16.V5 MAb is reactive with H11:
16[172–505] but not H16:11[171–505].
Dilution of positive control
Type-specific MAbs were used as positive controls/
internal standards. To determine the optimal dilution,
HPV16 and HPV11 VLPs were coated onto microtiter
plates in cold PBS overnight. After blocking with 10%
horse serum in phosphate-buffered saline (HS-PBS) for
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1 h at room temperature, 1:100, 1:1,000, 1:10,000,
1:100,000, 1:1,000,000, 1:10,000,000 and 1:100,000,000
serial 10-fold dilutions of MAbs H16.V5, H11.F1, and
H11.H3 were added. Following a 2-h incubation at room
temperature, goat antimouse IgG-horseradish peroxidase
conjugate (1:2,000) diluted in 10% HS-PBS was added
for a 1-h reaction at room temperature. The highest di-
lution giving maximal reactivity with homologous VLPs
was used in subsequent experiments (1:1,000,000 for
H16.V5, 1:100,000 for H11.F1 and 1:10,000 for
H11.H3).
Coating concentration
The coating concentrations of HPV16, HPV11 VLP
and the three hybrid VLPs H11:16[172–505], H11:
16[FGHI] and H16:11[171–505] were determined by
using serial dilution: five twofold serial dilutions were
coated onto microtiter plates in cold PBS overnight. After
blocking for 1 h with 10% horse serum in PBS (HS–PBS)
at room temperature, the MAb H16.V5 diluted
1:1,000,000 was added onto the wells which were coated
with HPV16 VLP, hybrid H11:16[172–505], and H11:
16[FGHI]. MAb H11.F1 at 1:100,000 was added to the
wells which were coated with HPV11 VLP and MAb
H11.H3 at 1:10,000 was added to the wells, which were
coated with HPV11 VLP and H16:11[171–505]. Follow-
ing a 2-h reaction at room temperature, goat antimouse
IgG-horseradish peroxidase conjugate (1:2000 diluted in
10% HS-PBS) was added for a 1-h incubation at room
temperature. The highest dilution giving maximal reac-
tivity was used as coating concentration in subsequent
experiments.
Fig. 4. Reactivity of HPV16/11 hybrid virus-like particles with HPV16 negative and HPV11 negative control serum samples from children. (A) Hybrid
H11:16[FGHI] vs HPV11. (B) Hybrid H16:11[171-505] vs HPV11. (C) Hybrid H11:16[FGHI] vs hybrid H16:11[171-505].
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ELISA using hybrid VLP
Intact HPV16, HPV11 capsids and hybrid VLPs H11:
16[172–505], H11:16[FGHI], and H16:11[171–505] were
coated onto microtiter plates in cold PBS at pH 7.2 over-
night. For generation of disrupted VLPs by alkaline treat-
ment, the VLPs were incubated for 4 h at room temperature
in 0.1 M carbonate buffer (pH 9.6), thereafter the denatured
antigen was coated overnight. Disrupted bovine papilloma-
virus (BPV) capsids were used as negative control in all
assays. After the plates were washed once with PBS–0.5%
Tween 20 (PBS-T), they were blocked with 10% HS–PBS
at room temperature for 1 h. Then Selected human serum
samples were added in duplicate at 1:30 dilution in HS-PBS
for a 2-h reaction at room temperature. Six wells in each
plate were incubated only with 10% HS–PBS and were
prepared for later addition of the positive controls H16.V5,
H11.F1, and H11.H3 in duplicate. Following five thorough
washings of the plates with PBS–0.5% Tween 20 (PBS-T),
a monoclonal antibody to human IgG, 1:800 diluted in 10%
HS–PBS, was added; MAb positive controls V5 at a
1:1,000,000 dilution, F1 at a 1:100,000 dilution, and H3 at
a 1:10,000 dilution were added to the wells that were pre-
viously incubated only with HS–PBS. The plates were in-
cubated for 90 min at room temperature. After washing the
plates, goat antimouse IgG HRP conjugate, 1:2000 diluted
in HS–PBS, were added for 1 h at room temperature, fol-
lowed by addition of substrate. The absorbance of each
serum with disrupted BPV was subtracted from the HPV
and hybrid VLP reactivity, and then the mean value of the
duplicates was calculated.
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